Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Rheumatol ; 13(2): 239-43, 1994 Jun.
Article in English | MEDLINE | ID: mdl-8088066

ABSTRACT

Pericardial and lung involvement in rheumatoid arthritis (RA), suspected to be less severe in a developing nation (Turkey), have been evaluated. We have studied clinical, echocardiographic and pulmonary findings (radiological and functional) in 93 consecutive Turkish patients with definite/classical RA. Findings were compared with those of a group of patients with osteoarthritis or local rheumatological conditions (n = 60) in a blind protocol. Fifty patients with systemic lupus (SLE) were studied as a high risk control group for pericardial involvement. While pericardial disease was detected in 5.5% (5/90) of RA patients, it was detected in 6.6% (4/60) of the control patients. SLE patients had a 26% (13/50) prevalence. Interstitial lung disease was found in 27.7% of RA patients but it was present in 6.6% (4/60) of the control patients. We observed that a group of patients with RA in Turkey had a low prevalence of pericardial disease. This is further evidence that RA has a mild course in developing countries.


Subject(s)
Arthritis, Rheumatoid/complications , Lung Diseases/etiology , Pericardial Effusion/etiology , Adult , Aged , Echocardiography , Female , Humans , Lung/diagnostic imaging , Lung/physiopathology , Lung Diseases/diagnostic imaging , Lung Diseases/physiopathology , Male , Middle Aged , Pericardial Effusion/diagnostic imaging , Radiography , Respiratory Function Tests , Smoking , Turkey
3.
J Int Med Res ; 17(3): 268-76, 1989.
Article in English | MEDLINE | ID: mdl-2767329

ABSTRACT

The efficacy of sustained-release verapamil as a first-stage treatment for mild to moderate, uncomplicated essential hypertension was studied. Nineteen patients aged 36-70 years (mean +/- SD 55 +/- 10 years) entered the study. Treatment with 240 mg sustained-release verapamil, once daily for 8 weeks, caused systolic and diastolic blood pressures to decline significantly during the first 2 weeks and this lower level was maintained until week 8. Heart rate decreased gradually during the treatment period reaching significance at week 8. After 2 weeks maximum systolic and diastolic blood pressures during isometric exercise were significantly reduced compared with pre-treatment values; there was no difference in the percentage increase occurring pre- and post-treatment. These measures for heart rate did not change significantly. Except for a significant reduction in cardiac index after 8 weeks left ventricular function and left ventricular mass were unchanged. The 24-h urinary Na+ excretion increased significantly after 2 and 8 weeks' treatment. Plasma renin activity, serum lipid concentrations and routine blood chemistries were not affected. Side-effects were transient and did not require discontinuation of therapy. In conclusion, sustained-release verapamil is an efficacious and well tolerated first-stage drug in the treatment of essential hypertension.


Subject(s)
Hypertension/drug therapy , Verapamil/therapeutic use , Blood Pressure/drug effects , Delayed-Action Preparations , Electrocardiography , Female , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Isometric Contraction , Male , Middle Aged , Physical Exertion
SELECTION OF CITATIONS
SEARCH DETAIL
...